Resiquimod and other immune response modifiers as vaccine adjuvants

References

• Singh M, Ugozzoli M, Kazzaz J et al. A preliminary evaluation of alternative adjuvants to alum using a range of established and new generation vaccine antigens. Vaccine24(10), 1680–1686 (2006).
   PubMed Web of Science ®Google Scholar
• Ott G, Barchfeld GL, Chernoff D et al. MF59. Design and evaluation of a safe and potent adjuvant for human vaccines. Pharm. Biotechnol.6, 277–296 (1995).
   PubMedGoogle Scholar
• Medzhitov R. Toll-like receptors and innate immunity. Nat. Rev. Immunol.1(2), 135–145 (2001).
   PubMed Web of Science ®Google Scholar
• Takeda K, Akira S. Toll-like receptors in innate immunity. Int. Immunol.17(1), 1–14 (2005).
   PubMed Web of Science ®Google Scholar
• Akira S, Hemmi H. Recognition of pathogen-associated molecular patterns by TLR family. Immunol. Lett.85(2), 85–95 (2003).
   PubMed Web of Science ®Google Scholar
• Beutler B, Jiang Z, Georgel P et al. Genetic analysis of host resistance: Toll-like receptor signaling and immunity at large. Annu. Rev. Immunol.24, 353–389 (2006).
   PubMed Web of Science ®Google Scholar
• Giannini SL, Hanon E, Moris P et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine24(33–34), 5937–5949 (2006).
   PubMed Web of Science ®Google Scholar
• Diebold SS, Kaisho T, Hemmi H, Akira S, Reis E, Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science303(5663), 1529–1531 (2004).
   PubMed Web of Science ®Google Scholar
• Heil F, Hemmi H, Hochrein H et al. Species-specific recognition of single-stranded RNA via Toll-like receptor 7 and 8. Science303(5663), 1526–1529 (2004).
   PubMed Web of Science ®Google Scholar
• Heil F, Ahmad-Nejad P, Hemmi H et al. The Toll-like receptor 7 (TLR7)-specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily. Eur. J. Immunol.33(11), 2987–2997 (2003).
   PubMed Web of Science ®Google Scholar
• Hemmi H, Kaisho T, Takeuchi O et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Immunol.3(2), 196–200 (2002).
   PubMed Web of Science ®Google Scholar
• Horsmans Y, Berg T, Desager JP et al. Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection. Hepatology42(3), 724–731 (2005).
   PubMed Web of Science ®Google Scholar
• Lee J, Wu CC, Lee KJ et al. Activation of anti-hepatitis C virus responses via Toll-like receptor 7. Proc. Natl Acad. Sci. USA103(6), 1828–1833 (2006).
   PubMed Web of Science ®Google Scholar
• Gorden KB, Gorski KS, Gibson SJ et al. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J. Immunol.174(3), 1259–1268 (2005).
   PubMed Web of Science ®Google Scholar
• Jurk M, Heil F, Vollmer J et al. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat. Immunol.3(6), 499 (2002).
   PubMed Web of Science ®Google Scholar
• Hornung V, Rothenfusser S, Britsch S et al. Quantitative expression of Toll-like receptor 1–10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J. Immunol.168(9), 4531–4537 (2002).
   PubMed Web of Science ®Google Scholar
• Jarrossay D, Napolitani G, Colonna M, Sallusto F, Lanzavecchia A. Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells. Eur. J. Immunol.31(11), 3388–3393 (2001).
   PubMed Web of Science ®Google Scholar
• Hattermann K, Picard S, Borgeat M, Leclerc P, Pouliot M, Borgeat P. The Toll-like receptor 7/8-ligand resiquimod (R-848) primes human neutrophils for leukotriene B4, prostaglandin E2 and platelet-activating factor biosynthesis. FASEB J.21, 1575–1585 (2007).
   PubMed Web of Science ®Google Scholar
• Peng G, Guo Z, Kiniwa Y et al. Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function. Science309(5739), 1380–1384 (2005).
   PubMed Web of Science ®Google Scholar
• Asselin-Paturel C, Brizard G, Chemin K et al. Type I interferon dependence of plasmacytoid dendritic cell activation and migration. J. Exp. Med.201(7), 1157–1167 (2005).
   PubMed Web of Science ®Google Scholar
• Doxsee CL, Riter TR, Reiter MJ et al. The immune response modifier and Toll-like receptor 7 agonist S-27609 selectively induces IL-12 and TNF-α production in CD11c+CD11b+CD8- dendritic cells. J. Immunol.171(3), 1156–1163 (2003).
   PubMed Web of Science ®Google Scholar
• Gorden KK, Qiu XX, Binsfeld CC, Vasilakos JP, Alkan SS. Cutting edge: activation of murine TLR8 by a combination of imidazoquinoline immune response modifiers and polyT oligodeoxynucleotides. J. Immunol.177(10), 6584–6587 (2006).
   PubMed Web of Science ®Google Scholar
• Goodman MG. A new approach to vaccine adjuvants. Immunopotentiation by intracellular T-helper-like signals transmitted by loxoribine. Pharm. Biotechnol.6, 581–609 (1995).
   PubMedGoogle Scholar
• Tsukamoto Y, Uehara S, Mizoguchi C et al. Requirement of 8-mercaptoguanosine as a costimulus for IL-4-dependent μ to γ1 class switch recombination in CD38-activated B cells. Biochem. Biophys. Res. Commun.336(2), 625–633 (2005).
   PubMed Web of Science ®Google Scholar
• Bernstein DI, Harrison CJ. Effects of the immunomodulating agent R837 on acute and latent herpes simplex virus type 2 infections. Antimicrob. Agents Chemother.33(9), 1511–1515 (1989).
   PubMed Web of Science ®Google Scholar
• Harrison CJ, Jenski L, Voychehovski T, Bernstein DI. Modification of immunological responses and clinical disease during topical R-837 treatment of genital HSV-2 infection. Antiviral Res.10(4–5), 209–223 (1988).
   PubMed Web of Science ®Google Scholar
• Gibson SJ, Imbertson LM, Wagner TL et al. Cellular requirements for cytokine production in response to the immunomodulators imiquimod and S-27609. J. Interferon Cytokine Res.15(6), 537–545 (1995).
   PubMed Web of Science ®Google Scholar
• Gibson SJ, Lindh JM, Riter TR et al. Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod. Cell. Immunol.218(1–2), 74–86 (2002).
   PubMed Web of Science ®Google Scholar
• Tomai MA, Gibson SJ, Imbertson LM et al. Immunomodulating and antiviral activities of the imidazoquinoline S-28463. Antiviral Res.28(3), 253–264 (1995).
   PubMed Web of Science ®Google Scholar
• Ahonen CL, Gibson SJ, Smith RM et al. Dendritic cell maturation and subsequent enhanced T-cell stimulation induced with the novel synthetic immune response modifier R-848. Cell. Immunol.197(1), 62–72 (1999).
   PubMed Web of Science ®Google Scholar
• Gorski KS, Waller EL, Bjornton-Severson J et al. Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists. Int. Immunol.18(7), 1115–1126 (2006).
   PubMed Web of Science ®Google Scholar
• Kanneganti TD, Ozoren N, Body-Malapel M et al. Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3. Nature440(7081), 233–236 (2006).
   PubMed Web of Science ®Google Scholar
• Wagner TL, Ahonen CL, Couture AM et al. Modulation of Th1 and Th2 cytokine production with the immune response modifiers, R-848 and imiquimod. Cell. Immunol.191(1), 10–19 (1999).
   PubMed Web of Science ®Google Scholar
• Hart OM, Athie-Morales V, O’Connor GM, Gardiner CM. TLR7/8-mediated activation of human NK cells results in accessory cell-dependent IFN-γ production. J. Immunol.175(3), 1636–1642 (2005).
   PubMed Web of Science ®Google Scholar
• Tabeta K, Hoebe K, Janssen EM et al. The Unc93b1 mutation 3d disrupts exogenous antigen presentation and signaling via Toll-like receptors 3, 7 and 9. Nat. Immunol.7(2), 156–164 (2006).
   PubMed Web of Science ®Google Scholar
• Gohda J, Matsumura T, Inoue J. Cutting edge: TNFR-associated factor (TRAF) 6 is essential for MyD88-dependent pathway but not Toll/IL-1 receptor domain-containing adaptor-inducing IFN-β (TRIF)-dependent pathway in TLR signaling. J. Immunol.173(5), 2913–2917 (2004).
   PubMed Web of Science ®Google Scholar
• Honda K, Yanai H, Negishi H et al. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature434(7034), 772–777 (2005).
   PubMed Web of Science ®Google Scholar
• Schoenemeyer A, Barnes BJ, Mancl ME et al. The interferon regulatory factor, IRF5, is a central mediator of Toll-like receptor 7 signaling. J. Biol. Chem.280(17), 17005–17012 (2005).
   PubMed Web of Science ®Google Scholar
• Takaoka A, Yanai H, Kondo S et al. Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors. Nature434(7030), 243–249 (2005).
   PubMed Web of Science ®Google Scholar
• Bishop GA, Hsing Y, Hostager BS et al. Molecular mechanisms of B lymphocyte activation by the immune response modifier R-848. J. Immunol.165(10), 5552–5557 (2000).
   PubMed Web of Science ®Google Scholar
• Tomai MA, Imbertson LM, Stanczak TL, Tygrett LT, Waldschmidt TJ. The immune response modifiers imiquimod and R-848 are potent activators of B lymphocytes. Cell. Immunol.203(1), 55–65 (2000).
   PubMed Web of Science ®Google Scholar
• Bekeredjian-Ding IB, Wagner M, Hornung V et al. Plasmacytoid dendritic cells control TLR7 sensitivity of naive B cells via type I IFN. J. Immunol.174(7), 4043–4050 (2005).
   PubMed Web of Science ®Google Scholar
• Lore K, Betts MR, Brenchley JM et al. Toll-like receptor ligands modulate dendritic cells to augment cytomegalovirus- and HIV-1-specific T cell responses. J. Immunol.171(8), 4320–4328 (2003).
   PubMed Web of Science ®Google Scholar
• Xu S, Koldovsky U, Xu M et al. High-avidity antitumor T-cell generation by Toll receptor 8-primed, myeloid-derived dendritic cells is mediated by IL-12 production. Surgery140(2), 170–178 (2006).
   PubMed Web of Science ®Google Scholar
• Brugnolo F, Sampognaro S, Liotta F et al. The novel synthetic immune response modifier R-848 (Resiquimod) shifts human allergen-specific CD4+ Th2 lymphocytes into IFN-γ-producing cells. J. Allergy Clin. Immunol.111(2), 380–388 (2003).
   PubMed Web of Science ®Google Scholar
• Caron G, Duluc D, Fremaux I et al. Direct stimulation of human T cells via TLR5 and TLR7/8: flagellin and R-848 up-regulate proliferation and IFN-γ production by memory CD4+ T cells. J. Immunol.175(3), 1551–1557 (2005).
   PubMed Web of Science ®Google Scholar
• Ramakrishna V, Vasilakos JP, Tario JD Jr. et al. Toll-like receptor activation enhances cell-mediated immunity induced by an antibody vaccine targeting human dendritic cells. J. Transl. Med.5, 5 (2007).
   PubMed Web of Science ®Google Scholar
• Harrison CJ, Miller RL, Bernstein DI. Posttherapy suppression of genital herpes simplex virus (HSV) recurrences and enhancement of HSV-specific T-cell memory by imiquimod in guinea pigs. Antimicrob. Agents Chemother.38(9), 2059–2064 (1994).
   PubMed Web of Science ®Google Scholar
• Harrison CJ, Miller RL, Bernstein DI. Reduction of recurrent HSV disease using imiquimod alone or combined with a glycoprotein vaccine. Vaccine19(13–14), 1820–1826 (2001).
   PubMed Web of Science ®Google Scholar
• Slade HB, Owens ML, Tomai MA, Miller RL. Imiquimod 5% cream (Aldara). Expert Opin. Investig. Drugs7(3), 437–449 (1998).
   PubMedGoogle Scholar
• Edwards L, Ferenczy A, Eron L et al. Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human Papilloma Virus. Arch. Dermatol.134(1), 25–30 (1998).
   PubMed Web of Science ®Google Scholar
• Chakrabarty A, Geisse JK. Medical therapies for non-melanoma skin cancer. Clin. Dermatol.22(3), 183–188 (2004).
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Dinehart S, Whiting D et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from two Phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J. Am. Acad. Dermatol.50(5), 714–721 (2004).
   PubMed Web of Science ®Google Scholar
• Arany I, Tyring SK, Stanley MA et al. Enhancement of the innate and cellular immune response in patients with genital warts treated with topical imiquimod cream 5%. Antiviral Res.43(1), 55–63 (1999).
   PubMed Web of Science ®Google Scholar
• Barnetson RS, Satchell A, Zhuang L, Slade HB, Halliday GM. Imiquimod induced regression of clinically diagnosed superficial basal cell carcinoma is associated with early infiltration by CD4 T cells and dendritic cells. Clin. Exp. Dermatol.29(6), 639–643 (2004).
   PubMed Web of Science ®Google Scholar
• Urosevic M, Dummer R, Conrad C et al. Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment. J. Natl Cancer Inst.97(15), 1143–1153 (2005).
   PubMed Web of Science ®Google Scholar
• Meng Y, Carpentier AF, Chen L et al. Successful combination of local CpG-ODN and radiotherapy in malignant glioma. Int. J. Cancer116(6), 992–997 (2005).
   PubMed Web of Science ®Google Scholar
• Redondo P, Del Olmo J, Lopez-Diaz de Cerio A et al. Imiquimod enhances the systemic immunity attained by local cryosurgery destruction of melanoma lesions. J. Invest. Dermatol.127, 1673–1680 (2007).
   PubMed Web of Science ®Google Scholar
• Naylor MF, Chen WR, Teague TK, Perry LA, Nordquist RE. In situ photoimmunotherapy: a tumour-directed treatment for melanoma. Br. J. Dermatol.155(6), 1287–1292 (2006).
   PubMed Web of Science ®Google Scholar
• Bernstein DI, Miller RL, Harrison CJ. Adjuvant effects of imiquimod on a herpes simplex virus type 2 glycoprotein vaccine in guinea pigs. J. Infect. Dis.167(3), 731–735 (1993).
   PubMed Web of Science ®Google Scholar
• Vasilakos JP, Smith RM, Gibson SJ et al. Adjuvant activities of immune response modifier R-848: comparison with CpG ODN. Cell. Immunol.204(1), 64–74 (2000).
   PubMed Web of Science ®Google Scholar
• Johansen P, Senti G, Martinez Gomez J et al. Toll-like receptor ligands as adjuvants in allergen-specific immunotherapy. Clin. Exp. Allergy35, 1591–1598 (2005).
   PubMed Web of Science ®Google Scholar
• Thomsen LL, Topley P, Daly MG, Brett SJ, Tite JP. Imiquimod and resiquimod in a mouse model: adjuvants for DNA vaccination by particle-mediated immunotherapeutic delivery. Vaccine22(13–14), 1799–1809 (2004).
   PubMed Web of Science ®Google Scholar
• Otero M, Calarota SA, Felber B et al. Resiquimod is a modest adjuvant for HIV-1 gag-based genetic immunization in a mouse model. Vaccine22(13–14), 1782–1790 (2004).
   PubMed Web of Science ®Google Scholar
• Smorlesi A, Papalini F, Orlando F et al. Imiquimod and S-27609 as adjuvants of DNA vaccination in a transgenic murine model of HER2/neu-positive mammary carcinoma. Gene Ther.12(17), 1324–1332 (2005).
   PubMed Web of Science ®Google Scholar
• Wille-Reece U, Flynn BJ, Lore K et al. Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime–boost immunization in nonhuman primates. J. Exp. Med.203(5), 1249–1258 (2006).
   PubMed Web of Science ®Google Scholar
• Wille-Reece U, Flynn BJ, Lore K et al. HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates. Proc. Natl Acad. Sci. USA102(42), 15190–15194 (2005).
   PubMed Web of Science ®Google Scholar
• Wille-Reece U, Wu CY, Flynn BJ, Kedl RM, Seder RA. Immunization with HIV-1 Gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 Gag-specific Th1 and CD8+ T cell responses. J. Immunol.174(12), 7676–7683 (2005).
   PubMed Web of Science ®Google Scholar
• Weeratna RD, Makinen SR, McCluskie MJ, Davis HL. TLR agonists as vaccine adjuvants: comparison of CpG ODN and resiquimod (R-848). Vaccine23(45), 5263–5270 (2005).
   PubMed Web of Science ®Google Scholar
• Imbertson LM, Beaurline JM, Couture AM et al. Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463. J. Invest. Dermatol.110(5), 734–739 (1998).
   PubMed Web of Science ®Google Scholar
• Suzuki H, Wang B, Shivji GM et al. Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. J. Invest. Dermatol.114(1), 135–141 (2000).
   PubMed Web of Science ®Google Scholar
• Nair S, McLaughlin C, Weizer A et al. Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation. J. Immunol.171(11), 6275–6282 (2003).
   PubMed Web of Science ®Google Scholar
• Johnston D, Bystryn JC. Topical imiquimod is a potent adjuvant to a weakly-immunogenic protein prototype vaccine. Vaccine24(11), 1958–1965 (2006).
   PubMed Web of Science ®Google Scholar
• Zuber AK, Brave A, Engstrom G et al. Topical delivery of imiquimod to a mouse model as a novel adjuvant for human immunodeficiency virus (HIV) DNA. Vaccine22(13–14), 1791–1798 (2004).
   PubMed Web of Science ®Google Scholar
• Prins RM, Craft N, Bruhn KW et al. The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity. J. Immunol.176(1), 157–164 (2006).
   PubMed Web of Science ®Google Scholar
• Rechtsteiner G, Warger T, Osterloh P, Schild H, Radsak MP. Cutting edge: priming of CTL by transcutaneous peptide immunization with imiquimod. J. Immunol.174(5), 2476–2480 (2005).
   PubMed Web of Science ®Google Scholar
• Itoh T, Celis E. Transcutaneous immunization with cytotoxic T-cell peptide epitopes provides effective antitumor immunity in mice. J. Immunother.28(5), 430–437 (2005).
   PubMed Web of Science ®Google Scholar
• McCluskie MJ, Cartier JL, Patrick AJ et al. Treatment of intravaginal HSV-2 infection in mice: a comparison of CpG oligodeoxynucleotides and resiquimod (R-848). Antiviral Res.69(2), 77–85 (2006).
   PubMed Web of Science ®Google Scholar
• Clejan S, Mandrea E, Pandrea IV et al. Immune responses induced by intranasal imiquimod and implications for therapeutics in rhinovirus infections. J. Cell. Mol. Med.9(2), 457–461 (2005).
   PubMed Web of Science ®Google Scholar
• Savage P, Horton V, Moore J et al. A Phase I clinical trial of imiquimod, an oral interferon inducer, administered daily. Br. J Cancer74(9), 1482–1486 (1996).
   PubMed Web of Science ®Google Scholar
• Package insert info, Aldara, 3M Pharmaceuticals (2004).
   Google Scholar
• Spruance SL, Tyring SK, Smith MH, Meng TC. Application of a topical immune response modifier, resiquimod gel, to modify the recurrence rate of recurrent genital herpes: a pilot study. J. Infect. Dis.184(2), 196–200 (2001).
   PubMed Web of Science ®Google Scholar
• Sauder DN, Smith MH, Senta-McMillian T, Soria I, Meng TC. Randomized, single-blind, placebo-controlled study of topical application of the immune response modulator resiquimod in healthy adults. Antimicrob. Agents Chemother.47(12), 3846–3852 (2003).
   PubMed Web of Science ®Google Scholar
• Todd RW, Steele JC, Etherington I, Luesley DM. Detection of CD8+ T cell responses to human papillomavirus type 16 antigens in women using imiquimod as a treatment for high-grade vulval intraepithelial neoplasia. Gynecol. Oncol.92(1), 167–174 (2004).
   PubMed Web of Science ®Google Scholar
• Shackleton M, Davis ID, Hopkins W et al. The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand. Cancer Immun.4, 9 (2004).
   PubMedGoogle Scholar
• Napolitani G, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat. Immunol.6(8), 769–776 (2005).
   PubMed Web of Science ®Google Scholar
• Gautier G, Humbert M, Deauvieau F et al. A type I interferon autocrine–paracrine loop is involved in Toll-like receptor-induced interleukin-12p70 secretion by dendritic cells. J. Exp. Med.201(9), 1435–1446 (2005).
   PubMed Web of Science ®Google Scholar
• Ahonen CL, Doxsee CL, McGurran SM et al. Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN. J. Exp. Med.199(6), 775–784 (2004).
   PubMed Web of Science ®Google Scholar
• Sanchez PJ, McWilliams JA, Haluszczak C, Yagita H, Kedl RM. Combined TLR/CD40 stimulation mediates potent cellular immunity by regulating dendritic cell expression of CD70 in vivo. J. Immunol.178(3), 1564–1572 (2007).
   PubMed Web of Science ®Google Scholar
• Warger T, Osterloh P, Rechtsteiner G et al. Synergistic activation of dendritic cells by combined Toll-like receptor ligation induces superior CTL responses in vivo. Blood108(2), 544–550 (2006).
   PubMed Web of Science ®Google Scholar
• Warger T, Rechtsteiner G, Schmid B et al. Transcutaneous immunization with imiquimod is amplified by CD40 ligation and results in sustained cytotoxic T-lymphocyte activation and tumor protection. Clin. Rev. Allergy Immunol.32(1), 57–66 (2007).
   PubMed Web of Science ®Google Scholar